Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space

Here’s a company that may make a splash in the cannabis-based pharmaceuticals space, and it’s not a producer like Canopy Growth Corp. (TSX:WEED)!

| More on:

Ignoring the immense hype drawn by marijuana of late is hard. Canada is going to be the first G7 nation to legalize the drug, and that’s going to have a substantial positive impact on the Canadian economy, as tax revenues come pouring in. All eyes will be on Canada and its producers, like Canopy Growth Corp. (TSX:WEED), in the coming years, as the nascent industry has the opportunity to mature, but the most remarkable part about legal weed isn’t the positive effect on the economy; it’s the profound positive it’ll have on society as well.

Think about the pharmaceutical industry for a moment.

Consider the massive profits they’ve enjoyed at the expense of consumers, many of whom have had no other choice but to open their wallets and pay whatever price is commanded by a particular ailment-relieving drug that’s prescribed by a doctor. Such favourable or patented drugs are what economists refer to as “perfectly inelastic goods,” or goods whose demand doesn’t change in conjunction with its price.

If a pharmaceutical company has a patent on a drug, or if it’s been proven to be the most effective at treating a particular ailment through clinical trials, a firm has the freedom to set its price, and that’s all there is to it. And if it’s been shown to improve the quality of life for a suffering individual, they’ll pay up for it.

We’ve witnessed some greedy business practices in the past that have taken advantage of the fact that some drugs are perfectly inelastic.

Think Martin Shkreli of Turing Pharmaceuticals, Michael Pearson of Valeant Pharmceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), and Mark Thompson of Concordia International Corp. (TSX:CXR)(NYSE:CXRX). They’ve set prices through the roof, and many suffering customers have had no choice but to pay the obscene amounts for drugs or continue to suffer.

It’s not just drug pricing that’s a cause for concern, though; the more insidious part of the story is the fact that many of today’s drugs have detrimental side effects that patients may not be aware of when their doctor prescribes a specific medication to them. Patients trust their doctors, and they take the medicines prescribed to them. It’s that simple.

For many of the patients who suffer from debilitating ailments like chronic pain, opioid-based medications prescribed by doctors may lead a patient down a very dark path to opioid addiction.

You’ve probably heard the stories of people whose lives were ruined because a simple opioid prescription from their doctors ended up spiraling into a full-blown addiction that led them to seek black market opioids on the streets.

The opioid crisis is a depressing story, and the most tragic part is that many cases of unintentional addiction could have been avoiding had marijuana or cannabinoid-based medications been prescribed as a substitute.

Despite the decriminalization of medical marijuana, the drug has still had a stigma in the eyes of some physicians; in some instances, a doctor may even have the incentive to prescribe a particular medication for their benefit, whether or not it’s in the best interest of their patients.

That’s a significant reason why there’s an opioid epidemic right now, but the good news is that Canada’s legalization of marijuana will erode the taboo that’s been placed on marijuana for decades. Moreover, the education of the general public will likely increase as people become more comfortable discussing the topic of marijuana and its use in therapeutic purposes, not to mention that Canada can become a pioneer in the field of marijuana research.

With this in mind, Canadian pharmaceutical firms like Valeant ought to be interested in incorporating some marijuana-based products into its roster of drugs.

Valeant was domiciled in Canada because of tax purposes in the past, but now that the tax advantage is all but gone with U.S. corporate tax cuts, Valeant may wish to take advantage of the fact that it can produce marijuana and run clinical trials involving marijuana.

Who knows? Valeant may become like a GW Pharmaceuticals, plc as a pioneer in the field of medical marijuana research.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

worry concern
Investing

Is it Safe to Own U.S. Stocks These Days?

Alphabet (NASDAQ:GOOG) is a robust value bet, even after soaring 11% on the back of its quantum computing chip news.

Read more »

A worker drinks out of a mug in an office.
Dividend Stocks

A Dividend Giant I’d Buy Over BCE Stock Right Now

The largest telecom company in Canada is brutally discounted, and the dividend yield is naturally up, but it's too risky…

Read more »

a man celebrates his good fortune with a disco ball and confetti
Dividend Stocks

Get Ready to Invest $7,000 in This Dividend Stock for New Year Passive Income

This is the year you get ahead, and maxing out your TFSA contribution is the best way to start.

Read more »

ways to boost income
Dividend Stocks

Buy 2,653 Shares of This Top Dividend Stock for $10K in Annual Passive Income

Enbridge is a blue-chip TSX dividend stock that offers shareholders a forward yield of 6%. Is it still a good…

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, December 13

Down 1.1% week to date, the TSX Composite Index seems on track to end its five-week winning streak.

Read more »

ETF stands for Exchange Traded Fund
Bank Stocks

A Canadian Bank ETF I’d Buy With $1,000 and Hold Forever

This unique Hamilton ETF gives you 1.25x leveraged exposure to Canada's Big Six bank stocks.

Read more »

a person looks out a window into a cityscape
Dividend Stocks

1 Marvellous Canadian Dividend Stock Down 11% to Buy and Hold Immediately

Buying up this dividend stock while it's down isn't just a smart move, it could make you even more passive…

Read more »

Blocks conceptualizing the Registered Retirement Savings Plan
Dividend Stocks

CPP at 70: Is it Enough if Invested in an RRSP?

Even if you wait to take out CPP at 70, it's simply not going to cut it during retirement. Which…

Read more »